Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer.

However, this difference in PFS did not reach statistical significance (HR = 0.7076, 95%CI: 0.4069-1.23, P = 0.22) (Figure 2A ).

also in 111,027 other papers

Although the experimental group showed a trend toward improved PFS with combination therapy, it failed to demonstrate statistical significance, likely due to insufficient statistical power.

also in 53,322 other papers